FOXO1 and alveolar rhabdomyosarcoma: In a basic research, lipid-prostamine-siRNA (LPR) nanoparticles targeting PAX-FOXO1 inhibited the production of the fusion transcript and proliferation of RMS cells [62], and the LPR nanoparticles targeting PAX-FOXO1 significantly inhibited tumor growth in a xenograft model of ARMS.